Drug Approval | June 23, 2022
Menarini Group and Radius Health submit new drug application to the USFDA for Elacestrant
Intended for potential treatment of ER+/HER2- advanced or metastatic breast cancer patients
Intended for potential treatment of ER+/HER2- advanced or metastatic breast cancer patients
Brings 25 years of global operations and supply chain experience to Piramal
V116 designed to target serotypes that account for 85% of all invasive pneumococcal disease in individuals aged 65 and over in the United States as of 2019
LYNPARZA is approved in the U.S. for patients with HRR gene-mutated mCRPC (BRCA-mutated and other HRR gene mutations)
Bringing next-gen cannabinoid therapeutics to cancer patients
It is only the second healthcare provider in the world to attain the Stage 6 DIAM certification.
Indira IVF has established technological supremacy as the key differentiator, delivering industry leading success rate
This investment will facilitate a Cipla entity's strategic participation in the Poe diagnostics and AMR space through the design, development, and manufacturing of microfluidics-based technologies
Both manufacturing facilities are based out of Benguluru, India
Ganguly will execute company's strategic focus on leveraging CustomGlycan to develop novel therapeutics
Subscribe To Our Newsletter & Stay Updated
